Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Novo Sees Ozempic Boom Prompting Another Sales Surge
Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
‘Nature’s Ozempic' is an over-the-counter supplement. Does it live up to the hype?
The Cleveland Clinic also warns against buying into the “nature’s Ozempic” hype, but says the supplement could also aid in ...
Amy Schumer Lost 30 Lbs. on Ozempic — 'I Looked Great' — but Quit After Being ‘Bedridden’ with Nausea
Actress and comedian Amy Schumer said she took Ozempic three years ago and quickly lost 30 lbs. However, she quit the ...
Ozempic’s health benefits keep growing, but are the risks worth it?
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Researchers Present Ozempic Alternatives—Without Sickening GI Side Effects
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
An Ozempic Expert Explains What You Need to Know Before Taking GLP-1 Drugs
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
F.D.A. Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
Novo Nordisk Earnings Boost Stock in Ozempic Maker
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...